(Axios) – The obesity-drug race is becoming less about losing weight and more about keeping it off.

Why it matters: As more GLP-1 drugs deliver eye-popping results, the next winners may be determined by convenience, affordability and whether patients keep taking them long enough to benefit.

That means reducing side effects, focusing on lifestyle changes and making the pricey drugs affordable. (Read More)